Aerpio Pharmaceuticals(AADI) - 2025 Q4 - Annual Report

Table of Contents p UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38560 WHITEHAWK THERAPEUTICS, INC. (Exact name of Registrant as specified in its Charter) Delaware 61-1547850 (St ...